ACTC

Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer’s Disease

New Delhi, July 14, 2020: The Alzheimer's Clinical Trials Consortium (ACTC), Eisai Co., Ltd., and Biogen Inc. announced today that…

4 years ago